Log in

Relevant bibliographies by topics / Therapeutic risk / Journal articles

To see the other types of publications on this topic, follow the link: Therapeutic risk.

Journal articles on the topic 'Therapeutic risk'

Author: Grafiati

Published: 4 June 2021

Last updated: 6 February 2022

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Therapeutic risk.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

BORGES, LAUREN M., SARRA NAZEM, BRIDGET B. MATARAZZO, SEAN M. BARNES, and HAL S. WORTZEL. "Therapeutic Risk Management." Journal of Psychiatric Practice 25, no. 1 (2019): 46–53. http://dx.doi.org/10.1097/pra.0000000000000358.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

NAZEM, SARRA, CHRISTINE PAO, and HAL WORTZEL. "Therapeutic Risk Management." Journal of Psychiatric Practice 26, no. 3 (2020): 235–40. http://dx.doi.org/10.1097/pra.0000000000000465.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Corre, Jill, and Hervé Avet-Loiseau. "Risk-Based Therapeutic Strategies." Cancer Journal 25, no. 1 (2019): 54–58. http://dx.doi.org/10.1097/ppo.0000000000000352.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Felton, Anne, Nicola Wright, and Gemma Stacey. "Therapeutic risk-taking: A justifiable choice." BJPsych Advances 23, no. 2 (2017): 81–88. http://dx.doi.org/10.1192/apt.bp.115.015701.

Full text

Abstract:

SummaryTaking risks is a fundamental part of the human experience that supports personal growth. Therapeutic risk-taking enables patients to make decisions about their level of safety and to pursue goals. Promoting therapeutic risk-taking can be complex. Professionals can experience tension striving for a balance between the interests of the individual and societal pressures to control risk. This article examines therapeutic risk-taking, recognising the challenges to supporting it in practice and debating how they may be overcome.Learning Objectives• Be able to explain what therapeutic risk-ta

APA, Harvard, Vancouver, ISO, and other styles

5

Mol, Peter. "Therapeutic Risk Management of Medicines." Drug Safety 37, no. 12 (2014): 1067–68. http://dx.doi.org/10.1007/s40264-014-0233-0.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

WORTZEL, HAL S., LAUREN M. BORGES, SEAN M. BARNES, et al. "Therapeutic Risk Management for Violence: Clinical Risk Assessment." Journal of Psychiatric Practice 26, no. 4 (2020): 313–19. http://dx.doi.org/10.1097/pra.0000000000000481.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Stickley, Theodore, and Anne Felton. "Promoting recovery through therapeutic risk taking." Mental Health Practice 9, no. 8 (2006): 26–30. http://dx.doi.org/10.7748/mhp2006.05.9.8.26.c1910.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Felton, Anne. "Therapeutic risk taking: what is it?" RIVISTA SPERIMENTALE DI FRENIATRIA, no. 3 (November 2015): 89–104. http://dx.doi.org/10.3280/rsf2015-003006.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Hartzema, Abraham G. "Therapeutic risk management: the pharmacist's role." International Journal of Pharmacy Practice 16, no. 4 (2008): 205–10. http://dx.doi.org/10.1211/ijpp.16.4.0001.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Liang, Fern Z. "Hospital Risk in Selecting Therapeutic Alternates." American Journal of Health-System Pharmacy 45, no. 5 (1988): 1052–59. http://dx.doi.org/10.1093/ajhp/45.5.1052.

Full text

APA, Harvard, Vancouver, ISO, and other styles

11

Reichert, Janice M. "mAb therapeutic products and risk management." mAbs 2, no. 1 (2010): 1–2. http://dx.doi.org/10.4161/mabs.2.1.10628.

Full text

APA, Harvard, Vancouver, ISO, and other styles

12

WORTZEL, HAL S., SEAN M. BARNES, KAILY A. CANNIZZARO, EDGAR J. VILLARREAL, BRIDGET B. MATARAZZO, and MICHAEL H. ALLEN. "Welfare Checks and Therapeutic Risk Management." Journal of Psychiatric Practice 25, no. 6 (2019): 470–74. http://dx.doi.org/10.1097/pra.0000000000000434.

Full text

APA, Harvard, Vancouver, ISO, and other styles

13

Kern, Winfried V. "Risk assessment and risk-based therapeutic strategies in febrile neutropenia." Current Opinion in Infectious Diseases 14, no. 4 (2001): 415–22. http://dx.doi.org/10.1097/00001432-200108000-00003.

Full text

APA, Harvard, Vancouver, ISO, and other styles

14

WORTZEL, HAL S., SEAN M. BARNES, GEORGIA GERARD, et al. "Therapeutic Risk Management for Violence: Stratifying Risk and Characterizing Violence." Journal of Psychiatric Practice 26, no. 6 (2020): 503–9. http://dx.doi.org/10.1097/pra.0000000000000510.

Full text

APA, Harvard, Vancouver, ISO, and other styles

15

Maier, Andreas, Julia Wiedemann, Felicitas Rapp, et al. "Radon Exposure—Therapeutic Effect and Cancer Risk." International Journal of Molecular Sciences 22, no. 1 (2020): 316. http://dx.doi.org/10.3390/ijms22010316.

Full text

Abstract:

Largely unnoticed, all life on earth is constantly exposed to low levels of ionizing radiation. Radon, an imperceptible natural occurring radioactive noble gas, contributes as the largest single fraction to radiation exposure from natural sources. For that reason, radon represents a major issue for radiation protection. Nevertheless, radon is also applied for the therapy of inflammatory and degenerative diseases in galleries and spas to many thousand patients a year. In either case, chronic environmental exposure or therapy, the effect of radon on the organism exposed is still under investigat

APA, Harvard, Vancouver, ISO, and other styles

16

Tourdot, Sophie, and Timothy P. Hickling. "Nonclinical immunogenicity risk assessment of therapeutic proteins." Bioanalysis 11, no. 17 (2019): 1631–43. http://dx.doi.org/10.4155/bio-2018-0246.

Full text

Abstract:

Therapeutic protein drugs have significantly improved the management of many severe and chronic diseases. However, their development and optimal clinical application are complicated by the induction of unwanted immune responses. Therapeutic protein-induced antidrug antibodies can alter drug pharmacokinetics and pharmacodynamics leading to impaired efficacy and occasionally serious safety issues. There has been a growing interest over the past decade in developing methods to assess the risk of unwanted immunogenicity during preclinical drug development, with the aim to mitigate the risk during

APA, Harvard, Vancouver, ISO, and other styles

17

Wormsley, Kenneth G. "Therapeutic achlorhydria and risk of gastric cancer." Gastroenterologia Japonica 24, no. 5 (1989): 585–96. http://dx.doi.org/10.1007/bf02773894.

Full text

APA, Harvard, Vancouver, ISO, and other styles

18

Mecca, Fabio, Enrica Favaro, and Claudio Marengo. "Sincope: clinic risk determination and therapeutic management." Clinical Management Issues 1, no. 2 (2007): 51–62. http://dx.doi.org/10.7175/cmi.v1i2.609.

Full text

Abstract:

Syncope is a frequent symptom characterizing a wide group of pathologies with very different prognosis. By this reason, it is necessary a careful risk stratification for a better patient management. For this aim medical history and physical examination are fundamental. Diagnostic exams complete and confirm diagnostic suspiciousness formulated by medical history and examination, but rarely give elements for unexpected diagnosis. Correct identification of pathological mechanism of syncope and determination of associated clinical risk allow the best patient management avoiding dangerous discharge

APA, Harvard, Vancouver, ISO, and other styles

19

Maulik, Nilanjana, and Juan A. Sanchez. "Risk Factors in Heart Disease: Therapeutic Interventions." Antioxidants & Redox Signaling 15, no. 7 (2011): 1765–67. http://dx.doi.org/10.1089/ars.2011.3981.

Full text

APA, Harvard, Vancouver, ISO, and other styles

20

HOMAIFAR, BEETA, BRIDGET MATARAZZO, and HAL S. WORTZEL. "Therapeutic Risk Management of the Suicidal Patient." Journal of Psychiatric Practice 19, no. 5 (2013): 406–9. http://dx.doi.org/10.1097/01.pra.0000435039.68179.70.

Full text

APA, Harvard, Vancouver, ISO, and other styles

21

WORTZEL, HAL S., BEETA HOMAIFAR, BRIDGET MATARAZZO, and LISA A. BRENNER. "Therapeutic Risk Management of the Suicidal Patient." Journal of Psychiatric Practice 20, no. 1 (2014): 63–67. http://dx.doi.org/10.1097/01.pra.0000442940.46328.63.

Full text

APA, Harvard, Vancouver, ISO, and other styles

22

MATARAZZO, BRIDGET B., BEETA Y. HOMAIFAR, and HAL S. WORTZEL. "Therapeutic Risk Management of the Suicidal Patient." Journal of Psychiatric Practice 20, no. 3 (2014): 220–24. http://dx.doi.org/10.1097/01.pra.0000450321.06612.7a.

Full text

APA, Harvard, Vancouver, ISO, and other styles

23

Höffken, K. "Therapeutic Aspects of Low-Risk Breast Cancer." Oncology Research and Treatment 13, no. 4 (1990): 237–43. http://dx.doi.org/10.1159/000216770.

Full text

APA, Harvard, Vancouver, ISO, and other styles

24

Geurts, Marjolein, Malcolm R. Macleod, Rainer Kollmar, Philip H. C. Kremer, and H. Bart van der Worp. "Therapeutic Hypothermia and the Risk of Infection." Critical Care Medicine 42, no. 2 (2014): 231–42. http://dx.doi.org/10.1097/ccm.0b013e3182a276e8.

Full text

APA, Harvard, Vancouver, ISO, and other styles

25

Eward, Ann Maxwell. "Book Review: Therapeutic Risk: Perception, Measurement, Management." DICP 23, no. 9 (1989): 719. http://dx.doi.org/10.1177/106002808902300933.

Full text

APA, Harvard, Vancouver, ISO, and other styles

26

Pokhrel, Laxman. "Alzheimer’s disease: Risk factors and therapeutic targets." Journal of Coastal Life Medicine 3, no. 9 (2015): 752–55. http://dx.doi.org/10.12980/jclm.3.2015j5-57.

Full text

APA, Harvard, Vancouver, ISO, and other styles

27

McCabe, Mike, and Stephen Pye. "Therapeutic Ultrasound: Risk Associated with Poor Calibration." Physiotherapy 83, no. 5 (1997): 228. http://dx.doi.org/10.1016/s0031-9406(05)66211-6.

Full text

APA, Harvard, Vancouver, ISO, and other styles

28

Yu, Tian, Vijayalakshmi Rajendran, May Griffith, John V. Forrester, and Lucia Kuffová. "High-risk corneal allografts: A therapeutic challenge." World Journal of Transplantation 6, no. 1 (2016): 10. http://dx.doi.org/10.5500/wjt.v6.i1.10.

Full text

APA, Harvard, Vancouver, ISO, and other styles

29

Foster, B. C. "Therapeutic product disposition in at-risk populations." Radiation Protection Dosimetry 134, no. 3-4 (2009): 184–90. http://dx.doi.org/10.1093/rpd/ncp071.

Full text

APA, Harvard, Vancouver, ISO, and other styles

30

PhD, Elizabeth Andrews, Alicia Gilsenan, and Suzanne Cook. "Therapeutic Risk Management Interventions: Feasibility and Effectiveness." Journal of the American Pharmacists Association 44, no. 4 (2004): 491–500. http://dx.doi.org/10.1331/1544345041475670.

Full text

APA, Harvard, Vancouver, ISO, and other styles

31

Garaventa, Alberto, and Giorgio Perilongo. "High risk neuroblastoma: A persistent therapeutic challenge." Pediatric Blood & Cancer 51, no. 6 (2008): 722–23. http://dx.doi.org/10.1002/pbc.21754.

Full text

APA, Harvard, Vancouver, ISO, and other styles

32

Wang, Chih-Hung, Nai-Chuan Chen, Min-Shan Tsai, et al. "Therapeutic Hypothermia and the Risk of Hemorrhage." Medicine 94, no. 47 (2015): e2152. http://dx.doi.org/10.1097/md.0000000000002152.

Full text

APA, Harvard, Vancouver, ISO, and other styles

33

Felton, Anne, Julie Repper, and Mark Avis. "Therapeutic relationships, risk, and mental health practice." International Journal of Mental Health Nursing 27, no. 3 (2017): 1137–48. http://dx.doi.org/10.1111/inm.12430.

Full text

APA, Harvard, Vancouver, ISO, and other styles

34

Sichilima, Tangu, and Michael J. Rieder. "Adderall and cardiovascular risk: A therapeutic dilemma." Paediatrics & Child Health 14, no. 3 (2009): 193–95. http://dx.doi.org/10.1093/pch/14.3.193.

Full text

APA, Harvard, Vancouver, ISO, and other styles

35

Aronne, Louis J. "Therapeutic Options for Modifying Cardiometabolic Risk Factors." American Journal of Medicine 120, no. 3 (2007): S26—S34. http://dx.doi.org/10.1016/j.amjmed.2007.01.005.

Full text

APA, Harvard, Vancouver, ISO, and other styles

36

Coelho-Filho, Otavio R., Leelakrishna Nallamshetty, and Raymond Y. Kwong. "Risk Stratification for Therapeutic Management and Prognosis." Heart Failure Clinics 5, no. 3 (2009): 437–55. http://dx.doi.org/10.1016/j.hfc.2009.02.010.

Full text

APA, Harvard, Vancouver, ISO, and other styles

37

Mittelman, Moshe. "Low-risk MDS: non-transplant therapeutic approach." Cellular Therapy and Transplantation 10, no. 2 (2021): 7–16. http://dx.doi.org/10.18620/ctt-1866-8836-2021-10-2-7-16.

Full text

APA, Harvard, Vancouver, ISO, and other styles

38

Clanet, Michel C., Jerry S. Wolinsky, Raymond J. Ashton, Hans-Peter Hartung, and Stephen C. Reingold. "Risk evaluation and monitoring in multiple sclerosis therapeutics." Multiple Sclerosis Journal 20, no. 10 (2013): 1306–11. http://dx.doi.org/10.1177/1352458513513207.

Full text

Abstract:

Background: Risk for multiple sclerosis (MS) disease-modifying therapies (DMT) must be assessed on an ongoing basis. Early concerns regarding the first-approved DMTs for MS have been mitigated, but recently licensed therapies have been linked to possibly greater risks. Objectives: The objective of this review is to discuss risk assessment in MS therapeutics based on an international workshop and comprehensive literature search and recommend strategies for risk assessment/monitoring. Results: Assessment and perception of therapeutic risks vary between patients, doctors and regulators. Acceptabi

APA, Harvard, Vancouver, ISO, and other styles

39

WORTZEL, HAL S., LAUREN M. BORGES, SUZANNE MCGARITY, et al. "Therapeutic Risk Management for Violence: Augmenting Clinical Risk Assessment With Structured Instruments." Journal of Psychiatric Practice 26, no. 5 (2020): 405–10. http://dx.doi.org/10.1097/pra.0000000000000495.

Full text

APA, Harvard, Vancouver, ISO, and other styles

40

Yang, Huei-Fan, Ying-Hsiang Chou, Hsueh-Ya Tsai, Hsien-Chun Tseng, Hsin-Lin Chen, and Yueh-Chun Lee. "Examination of therapeutic risk factors for radiotherapy interruption." Therapeutic Radiology and Oncology 4 (September 2020): 17. http://dx.doi.org/10.21037/tro-19-113.

Full text

APA, Harvard, Vancouver, ISO, and other styles

41

Barnum, Scott R. "Therapeutic Inhibition of Complement: Well Worth the Risk." Trends in Pharmacological Sciences 38, no. 6 (2017): 503–5. http://dx.doi.org/10.1016/j.tips.2017.03.009.

Full text

APA, Harvard, Vancouver, ISO, and other styles

42

MOON, MARY ANN. "Therapeutic Retinoids Do Not Raise Risk of Fracture." Clinical Endocrinology News 5, no. 6 (2010): 12. http://dx.doi.org/10.1016/s1558-0164(10)70204-2.

Full text

APA, Harvard, Vancouver, ISO, and other styles

43

Assmann, Gerd, Paul Cullen, Jean-Charles Fruchart, et al. "Implications of emerging risk factors for therapeutic intervention." Nutrition, Metabolism and Cardiovascular Diseases 15, no. 5 (2005): 373–81. http://dx.doi.org/10.1016/j.numecd.2005.06.011.

Full text

APA, Harvard, Vancouver, ISO, and other styles

44

Young, J. "Mecamylamine: new therapeutic uses and toxicity/risk profile." Clinical Therapeutics 23, no. 4 (2001): 532–65. http://dx.doi.org/10.1016/s0149-2918(01)80059-x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

45

Chabeda, Aleyo, Romana J. R. Yanez, Renate Lamprecht, Ann E. Meyers, Edward P. Rybicki, and Inga I. Hitzeroth. "Therapeutic vaccines for high-risk HPV-associated diseases." Papillomavirus Research 5 (June 2018): 46–58. http://dx.doi.org/10.1016/j.pvr.2017.12.006.

Full text

APA, Harvard, Vancouver, ISO, and other styles

46

Hoff, Steven F. "A Review of Pharmacoepidemiology and Therapeutic Risk Management." Drug Information Journal 42, no. 6 (2008): 635–36. http://dx.doi.org/10.1177/009286150804200611.

Full text

APA, Harvard, Vancouver, ISO, and other styles

47

Meyskens, F. L., and C. E. McLaren. "Chemoprevention, Risk Reduction, Therapeutic Prevention, or Preventive Therapy?" JNCI Journal of the National Cancer Institute 102, no. 24 (2010): 1815–17. http://dx.doi.org/10.1093/jnci/djq466.

Full text

APA, Harvard, Vancouver, ISO, and other styles

48

Kennedy, Colin. "Paediatric neurology: understanding risk and improving therapeutic choices." Lancet Neurology 10, no. 1 (2011): 15–16. http://dx.doi.org/10.1016/s1474-4422(10)70305-7.

Full text

APA, Harvard, Vancouver, ISO, and other styles

49

de Leon, George. "Therapeutic communities: AIDS/HIV risk and harm reduction." Journal of Substance Abuse Treatment 13, no. 5 (1996): 411–20. http://dx.doi.org/10.1016/s0740-5472(96)00118-3.

Full text

APA, Harvard, Vancouver, ISO, and other styles

50

Ferrer, E., R. Acal, A. Villagrasa, et al. "THERAPEUTIC INERTIA IN VASCULAR RISK UNIT: PP.33.347." Journal of Hypertension 28 (June 2010): e554. http://dx.doi.org/10.1097/01.hjh.0000379885.18350.f3.

Full text

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!